Emergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government

MT Newswires Live

09/09

Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.

The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.

It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.

Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.

Emergent BioSolutions shares were up close to 2% in recent premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566692548"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566692548\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566692548?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566692548","market":"sh","top_or_hot":-1,"title":"Emergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government","media":"MT Newswires Live","content":"<html><body><p> Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.</p><p>The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.</p><p>It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.</p><p>Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.</p><p>Emergent BioSolutions shares were up close to 2% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-09 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.</p><p>The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.</p><p>It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.</p><p>Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.</p><p>Emergent BioSolutions shares were up close to 2% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566692548","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566692548","pubTimestamp":1757419855,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emergent BioSolutions  said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.Emergent BioSolutions shares were up close to 2% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","EBS":"Emergent Biosolutions","BK4139":"生物科技"},"translate_title":"Emergent BioSolutions赢得美国政府5600万美元疫苗供应订单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1},"content_text":"Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.Emergent BioSolutions shares were up close to 2% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}